Myelin oligodendrocyte glycoprotein antibody and N -methyl- d -aspartate receptor antibody overlapping syndrome: insights from the recent case reports
Clinical and Experimental Immunology · 2024
DOI: 10.1093/cei/uxad109 ↗Kurz gefasst
Fallbericht in der Zeitschrift Clinical and Experimental Immunology, 2024. Verfasst von Bing-Qing Du und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. Hauptthemen laut MEDLINE: Anti-N-Methyl-D-Aspartate Receptor Encephalitis, Receptors, N-Methyl-D-Aspartate. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Zhejiang Provincial Natural Science Foundation of China.
Abstract (Originalsprache)
The overlapping of two or more types of neural autoantibodies in one patient has increasingly been documented in recent years. The coexistence of myelin oligodendrocyte glycoprotein (MOG) and N-methyl-d-aspartate receptor (NMDAR) antibodies is most common, which leads to a unique condition known as the MOG antibody and NMDAR antibody overlapping syndrome (MNOS). Here, we have reviewed the pathogenesis, clinical manifestations, paraclinical features, and treatment of MNOS. Forty-nine patients with MNOS were included in this study. They were young males with a median onset age of 23 years. No tumors were observed in the patients, and 24 of them reported prodromal symptoms. The most common clinical presentations were psychiatric symptoms (35/49) and seizures (25/49). Abnormalities on magnetic resonance imaging involved the brainstem (11/49), cerebellum (9/49), and parietal lobe (9/49). Most patients mostly responded to immunotherapy and had a good long-term prognosis. However, the overall recurrence rate of MNOS was higher than that of mono antibody-positive diseases. The existence of concurrent NMDAR antibodies should be suspected in patients with MOG antibody-associated disease having psychiatric symptoms, seizures, movement disorders, or autonomic dysfunction. Similarly, serum MOG antibody testing should be performed when patients with anti-NMDAR encephalitis present with atypical clinical manifestations, such as visual impairment and limb weakness, and neuroradiological findings, such as optic nerve, spinal cord, or infratentorial involvement or meningeal enhancement. Early detection of the syndrome and prompt treatment can be beneficial for these patients, and maintenance immunosuppressive therapy is recommended due to the high overall recurrence rate of the syndrome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
- Department of Neurology, Zhejiang Hospital, Hangzhou, China.
- Department of Neurology, Zhejiang Chinese Medicine and Western Medicine Integrated Hospital, Hangzhou, China.
ORCID-Profile: Yin-Xi Zhang
Förderung
- Zhejiang Provincial Natural Science Foundation of China
Zitieren
APA
Du, B. Q., Lai, Q. L., Li, E. C., Cai, M. T., Fang, G. L., Shen, C. H., Zhang, Y. X., & Ding, M. P. (2024). Myelin oligodendrocyte glycoprotein antibody and N -methyl- d -aspartate receptor antibody overlapping syndrome: insights from the recent case reports. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxad109
Vancouver
Du BQ, Lai QL, Li EC, Cai MT, Fang GL, Shen CH, et al. Myelin oligodendrocyte glycoprotein antibody and N -methyl- d -aspartate receptor antibody overlapping syndrome: insights from the recent case reports. Clinical and Experimental Immunology. 2024. doi:10.1093/cei/uxad109
BibTeX
@article{Du2024,
author = {Du, Bing-Qing and Lai, Qi-Lun and Li, Er-Chuang and Cai, Meng-Ting and Fang, Gao-Li and Shen, Chun-Hong and Zhang, Yin-Xi and Ding, Mei-Ping},
title = {Myelin oligodendrocyte glycoprotein antibody and N -methyl- d -aspartate receptor antibody overlapping syndrome: insights from the recent case reports},
journal = {Clinical and Experimental Immunology},
year = {2024},
doi = {10.1093/cei/uxad109}
}
EUVIMED